Results 111 to 120 of about 2,106 (148)

Pharmacogenomics of CYP2D6, CYP2C19, CYP2C9, and Clinical Determinants of Fluoxetine-Norfluoxetine Pharmacokinetics in Real-World Clinical Conditions. [PDF]

Pharmaceutics
de la Cruz CG, Thomas L, Mata-Martín C, González I, LLerena A, Peñas-Lledó EM.   +5 more
europepmc   +1 more source

Objective autonomic testing in isolated REM sleep behavior disorder: a cornerstone for clinical practice, research, and trial design. [PDF]

Sleep
Baldelli L, Provini F, Calandra-Buonaura G.   +2 more
europepmc   +1 more source

Plasma Markers of Astrocytic and Axonal Integrity in Idiopathic/Isolated REM Sleep Behavior Disorder (iRBD) as Predictors of Dementia with Lewy Bodies. [PDF]

Mov Disord
Delva A, Zatti C, Pelletier A, Montplaisir J, Gagnon JF, Kollmorgen G, Kam-Thong T, Kustermann T, Machado V, Postuma RB.   +9 more
europepmc   +1 more source

Unmasking the Prodrome: A Deep-Learning Bridge to Precision Diagnostics in Rapid Eye Movement Sleep Behavior Disorder. [PDF]

J Clin Neurol
Kwon KY.
europepmc   +1 more source

Longitudinal Trajectory of Multimodal Markers in a Patient with Isolated REM Sleep Behavior Disorder. [PDF]

Mov Disord
Choi S, Kim R, Woo KA, Shin JH, Yoon EJ, Kim H, Kim YK, Lee JY.   +7 more
europepmc   +1 more source

Glymphatic Function in Prodromal Parkinson's Disease: Associations With Symptoms, Gray Matter Volume, and Phenoconversion Risk. [PDF]

Eur J Neurol
Chen A, Kuang Z, Khong PL, Huang J, Wen J, Choi YS, Xu Y, Wu P, Wei X.   +8 more
europepmc   +1 more source

Association of DTI-ALPS Glymphatic Index With Differential Phenoconversion in Isolated REM Sleep Behavior Disorder: A Multi-Cohort MRI Study. [PDF]

Neurology
Ayral V, Pastor-Bernier A, Daneault V, Tremblay C, Filiatrault M, Haddad C, Gagnon JF, Postuma RB, Dušek P, Marecek S, Varga Z, Klein JC, Hu MT, Lehéricy S, Arnulf I, Vidailhet M, Corvol JC, ICEBERG Study Group, Rahayel S.   +18 more
europepmc   +1 more source

Actionable medications in Australian Vietnam War veterans: Implications for pre-emptive pharmacogenetic testing. [PDF]

Australas Psychiatry
Tan WLA, Mellor R, Bennett D, Shu D, Leite de Castro CWS, Voisey J, Guindalini C, Semmler A.   +7 more
europepmc   +1 more source

Case Report: Severe SIADH and QTc prolongation induced by escitalopram-quetiapine interaction in a CYP2C19 intermediate metabolizer at therapeutic doses. [PDF]

Front Pharmacol
Jiang Z, Qu X, Yan Z, Fang J, Lan J, Zhao X, Qi W.   +6 more
europepmc   +1 more source